The striking anti-tumor effects of GSK-3β inhibition in vitro were paralleled by a significant decrease in subcutaneous growth and bone metastasis in vivo of the osteotropic prostate cancer cell line PC-3M-Pro4. Here, GSK3B is linked to prostate carcinoma.